<DOC>
	<DOCNO>NCT01244438</DOCNO>
	<brief_summary>An open-label , non-randomized , single arm study ass safety , tolerability , pharmacokinetics FP-1039 give weekly intravenous ( IV ) administration advance endometrial cancer patient FGFR2-specific mutation . FP-1039 dose weekly start dose 16 mg/kg .</brief_summary>
	<brief_title>Study FP-1039 Subjects With Endometrial Cancers</brief_title>
	<detailed_description>FP-1039 administer intravenously 30 minute week . All enrolled subject monitor occurrence unacceptable toxicity . Subjects evidence disease progression unacceptable toxicity 4 dos FP-1039 may continue receive weekly treatment provide continue evidence disease progression unacceptable toxicity . Dosing discontinue subject evidence disease progression . Disease assess approximately every 2 month .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Inclusion criterion study participation : 1 . Evidence histologically cytologically proven metastatic locally advanced unresectable endometrial cancer bear either S252W P243R FGFR2 mutation . 2 . Female least 18 year age 3 . Performance status ≤ 1 ECOG Performance Status Scale 4 . Adequate cardiac function e.g. , NYHA Class I II 5 . Estimated life expectancy least 16 week 6 . Measurable evaluable disease physical radiologic examination 7 . Must recover adverse effect prior therapy time enrollment ≤ Grade 1 ( exclude alopecia ) 8 . Meets laboratory criterion specify per protocol . Exclusion Criteria study participation : 1 . Prior treatment inhibitor FGF/FGFR pathway 2 . Prior treatment follow : Cytotoxic chemotherapy ( include investigational cytotoxic agent ) biologic agent ( antibody , immune modulators , cytokine ) within 4 week , nitrosoureas mitomycin C within 6 week prior schedule first dose FP1039 A smallmolecule kinase inhibitor ( include investigational smallmolecule kinase inhibitor ) within 14 day ( 5 half life drug active metabolite ) schedule first dose FP1039 Any investigational therapy within 28 day first schedule dose FP1039 Note : Any eligibility question relate prior therapy include time prior therapy discuss decision agree Investigator Sponsor write prior subject enter study 3 . Known hypersensitivity component FP1039 4 . Current anticoagulation therapeutic dos warfarin ( lowdose warfarin ≤ 1mg/day permit ) 5 . PT/INR and/or PTT test result screen 1.3 x laboratory ULN . 6 . No exclusionary medical history describe per protocol . 7 . Presence follow condition : Luminal intestinal cancer and/or abdominal carcinomatosis History abdominal fistula , gastrointestinal perforation , peptic ulcer disease , intraabdominal abscess within 6 month prior study enrollment Other potential risk factor gastrointestinal perforation ( i.e. , acute diverticulitis , intraabdominal abscess , gastrointestinal obstruction ) 8 . History organ , bone marrow , stem cell transplantation 9 . Pregnant breast feed 10 . Clinically apparent CNS metastases carcinomatous meningitis Note : Subjects CNS metastasis complete course radiotherapy stable dose glucocorticoid least 4 week eligible . 11 . Uncontrolled intercurrent illness include limited active infection , hypertension , psychiatric , substance abuse disorder would preclude consent , limit compliance study requirement , confound safety interpretation . 12 . Unable unwilling abide study protocol cooperate fully Investigator designee</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>endometrial cancer</keyword>
	<keyword>FGFR2 mutation</keyword>
</DOC>